Taxane chemotherapy, including docetaxel in the front-line and cabazitaxel in the second-line setting, are mainstays of treatment for metastatic castration-resistant prostate cancer. In the phase 3 AFFINITY trial reported in The Lancet Oncology,¹ Tomasz Beer and colleagues investigated whether the addition of custirsen, an antisense oligonucleotide that targets the clusterin chaperone protein, improved overall survival when added to cabazitaxel in patients with metastatic castration-resistant prostate cancer that had progressed after previous docetaxel treatment.

中文翻译：

---

迈向转移性去势抵抗性前列腺癌的精准医学方法

紫杉烷化疗，包括一线多西他赛和二线卡巴他赛，是治疗转移性去势抵抗性前列腺癌的主要手段。在《柳叶刀肿瘤学》（The Lancet Oncology）报道的3期AFFINITY试验中，¹ Tomasz Beer及其同事研究了将卡斯他森（一种靶向于簇蛋白伴侣蛋白的反义寡核苷酸）添加到卡巴他赛中是否能改善转移性去势抵抗性前列腺癌患者的总体生存率。在先前的多西他赛治疗后进展。